<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GANCICLOVIR</span><br/>(gan-ci'clo-vir)<br/><span class="topboxtradename">Cytovene<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg capsules; 500 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Ganciclovir is an antiviral drug active against cytomegalovirus (CMV). It prevents the replication CMV DNA.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Sensitive human viruses include CMV, herpes simplex virus-1 and -2 (HSV-1, HSV-2), Epstein-Barr virus, and varicella-zoster
         virus.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>CMV retinitis, prophylaxis and treatment of systemic CMV infections in immunocompromised patients including HIV-positive and
         transplant patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ganciclovir or acyclovir, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, older adults, pregnancy (category C). Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Induction Therapy</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> &gt;<i>3 mo</i>, 5 mg/kg over 1 h q12h for 1421 d (doses may range from 2.55.0 mg/kg over 1 h q812h for 1035 d)<br/><br/><span class="indicationtitle">Maintenance Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5 mg/kg over 1 h qd or 6 mg/kg over 1 h qd 5 d/wk <span class="rdroute">PO</span> 1000 mg t.i.d. or 500 mg 6 times/d q3h while awake<br/><br/><span class="indicationtitle">Prevention of CMV Disease in Transplant Recipients</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 5 mg/kg q12h 714 d, then 5 mg/kg q.d. or 6 mg/kg/d 5 d/wk<br/><br/><span class="indicationtitle">CMV Infection after Bone Marrow Transplant</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 7.519.5 mg/kg/d divided q8h<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>See prescribing information for dosing in patients with renal impairment<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: Do not administer if neutrophil count falls below 500/mm<sup>3</sup> or platelet count falls below 25,000/mm<sup>3</sup>. 			
         </li>
<li>Avoid direct contact of powder in capsules or solution with skin and mucous membranes. Wash thoroughly with soap and water
            if contact occurs.
         </li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants and children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span>  Reconstitute the 500-mg vial using only 10 mL of sterile water (supplied) for injection immediately before use to yield 50
                  mg/mL. Shake well to dissolve. Withdraw the ordered amount and add to 100 mL of NS, D5W, or RL (volume less than 100 mL may be used, but the final concentration
                  should be 
               </p><p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give at a constant rate over 1 h. Avoid rapid infusion or bolus injection.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Amino acid solutions (TPN), bacteriostatic water for injection, <b>fludarabine, foscarnet, ondansetron.</b> <span class="incompattype">Y-site:</span> <b>Total parenteral nutrition.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solutions refrigerated at 4° C; use within 12 h.</li>
<li>Store infusion solution refrigerated up to 24 h of preparation.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Fever,</span> headache, disorientation, mental status changes, ataxia, <span class="speceff-life">coma</span>, confusion, dizziness, paresthesia, nervousness, somnolence, tremor. <span class="typehead">CV:</span> Edema, phlebitis. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, diarrhea,</span> anorexia, elevated liver enzymes. <span class="typehead">Hematologic:</span> <span class="speceff-life"> <i>Bone marrow suppression</i> </span> <i>,</i> <span class="speceff-common">thrombocytopenia, granulocytopenia, eosinophilia, leukopenia,</span> hyperbilirubinemia. <span class="typehead">Metabolic:</span> Hyperthermia, hypoglycemia. <span class="typehead">Urogenital:</span> Infertility. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">antineoplastic agents</span>, <b>amphotericin B,</b> <b>didanosine,</b> <b>trimethoprim-sulfa-methoxazole (TMP-SMZ),</b> <b>dapsone,</b> <b>pentamidine,</b> <b>probenecid,</b> <b>zidovudine</b> may increase bone marrow suppression and other toxic effects of ganciclovir; may increase risk of nephrotoxicity from <b>cyclosporine;</b> may increase risk of seizures due to <b>imipenem-cilastatin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 38 d. <span class="typehead">Duration:</span> Clinical relapse can occur 14 d to 3.5 mo after stopping therapy; positive blood and urine cultures recur 1260 d after
      therapy. <span class="typehead">Distribution:</span> Distributes throughout body including CSF, eye, lungs, liver, and kidneys; crosses placenta in animals; not known if distributed
      into breast milk. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 9499% of dose is excreted unchanged in urine. <span class="typehead">Half-Life:</span> 2.54.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Neutrophil and platelet counts at least every other day during twice-daily dosing and weekly thereafter; more frequent
            monitoring may be indicated in certain patients. Monitor serum creatinine or creatinine clearance at least q2wk. Closely monitor
            renal function in the older adult.
         </li>
<li>Inspect IV insertion site throughout infusion for signs and symptoms of phlebitis.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Drug is not a cure for CMV retinitis; follow regular ophthalmologic examination schedule. 						</li>
<li>Drink lots of fluids during therapy.</li>
<li>Use barrier contraception throughout therapy and for at least 90 d afterwards.</li>
<li>Maintain frequent hematologic monitoring.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>